TD Waterhouse Canada Inc. Trims Stake in Zoetis Inc. (NYSE:ZTS)

TD Waterhouse Canada Inc. cut its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 58.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,505 shares of the company's stock after selling 6,431 shares during the period. TD Waterhouse Canada Inc.'s holdings in Zoetis were worth $734,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its holdings in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the period. Murphy & Mullick Capital Management Corp bought a new position in Zoetis during the 4th quarter valued at approximately $44,000. Asset Planning Inc purchased a new stake in Zoetis in the 4th quarter worth approximately $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Zoetis during the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last ninety days. Insiders own 0.16% of the company's stock.

Zoetis Stock Up 0.3 %

Zoetis stock traded up $0.48 during mid-day trading on Wednesday, reaching $155.91. The stock had a trading volume of 1,119,042 shares, compared to its average volume of 2,993,029. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a 50-day moving average price of $158.81 and a two-hundred day moving average price of $167.98. The company has a market capitalization of $69.56 billion, a price-to-earnings ratio of 28.50, a PEG ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ZTS shares. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Stifel Nicolaus lowered their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of "Buy" and a consensus price target of $214.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.